Twitter Facebook LinkedIn YouTube

Abattis Bioceuticals (CSE: ATT) Announced Changes at the Management Level

Video Platform Video Management Video Solutions Video Player

Jaclyn Thomson, PhD joins the senior management team at the company’s Northern Vine Labs subsidiary, and Rene David, CFO, moves up to the Abattis Board of Directors.

Additional Information:

Company: Abattis Bioceuticals
Website: http://www.abattis.com
Stock Symbol: CSE: ATT
Date Published: Mar 13, 2017
Transcript: Available

Video Transcript:

I’m Bethany Rae for Investmentpitch media

Abattis Bioceuticals announced changes at the management level.

Jaclyn Thomson, PhD joins the senior management team at the company’s Northern Vine Labs subsidiary, and Rene David, CFO, moves up to the Abattis Board of Directors.

Abattis aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada.

The Northern Vine Labs subsidiary is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis.

The company’s other subsidiary, Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing, focusses on health products to penetrate the fast-growing market for natural, safe and effective products that meet unmet wellness needs.

Jacelyn will be responsible for lab operations and testing protocols while ensuring all transactions involving controlled substances comply with appropriate regulations and standards.

She brings a wide breadth of experience from her previous positions in quality assurance, scientific and regulatory consultation and research.

She is credited with publishing a highly successful academic manuscript regarding the extensive worldwide problem of Ginko Biloba adulteration in the journal Phytomedicine.

Rene David, CFO, stated: “Her appointment is a critical component of our overall strategy to position Northern Vine as the leader in not only the testing of, but also the subsequent formulations and science behind the cannabis plant. Jaclyn's in-depth knowledge of GMP as well as natural health products and Health Canada regulations means Northern Vine will maintain consistency with its procedures and ensure safe and reliable results on every product tested. Since receiving our Health Canada Dealers License in September of 2016, we have narrowed our focus on key pillars for future growth: testing and analytics; and, product sales into international markets through its wholly owned subsidiary, Vergence Bioceuticals. "

Jim Irving, Abattis Director, stated: “We are happy to have Rene join the Board. His experience as CFO and COO will provide us with valuable insight and practical solutions, to move the Company forward in the dynamic legal cannabis and nutraceutical industries in Canada and abroad.”

The shares are trading at $0.16 and with 114 million shares outstanding, the company is capitalized at $19.8 million.

For more information, please visit the company’s website www.abattis.com or contact Rene David, CFO, at 604-336-0881 or email news@abattis.com.

I’m Bethany Rae for Investmentpitch media